Partial
Mostly Aligned
Patient Risk:
Low
Summary
Overall partial alignment. The claims mirror some label concepts (hepatic and muscle safety/risks and CYP3A4 involvement) but many alcohol- or Lipitor-specific interaction claims are not supported or are only partially supported by the FDA label provided.
Category Scores
Accurate Statements
Higher atorvastatin levels can increase the risk of toxicity.
Supported by Skeletal Muscle (5.1) and Pharmacokinetics (12.3) discussions of exposure-toxicity relationships.
Statins can raise liver enzymes.
Supported by Liver Dysfunction (5.2) describing possible elevations in liver enzymes.
Healthcare provider can tailor advice to the individual's situation.
Supported by Patient Counseling Information (17).
If you notice signs of liver or muscle issues, tell your clinician.
Supported by 5.1 and 17 (patient warning language).
Fatigue, muscle aches, dark urine, or yellowing of skin/eyes can signal liver or muscle issues.
Partially supported by 5.1 (myopathy/rhabdomyolysis concepts) and 5.2 (liver function concerns); explicit symptom list is not a direct labeling quote but aligns with adverse effect concepts.
Unsupported Statements
Moderate wine consumption does not noticeably reduce atorvastatin efficacy in most people.
Not described in label; no efficacy interaction stated for alcohol in the provided sections.
A normal amount of alcohol (≈1–2 drinks) does not significantly alter CYP3A4 activity.
Label does not state that moderate alcohol intake alters CYP3A4 activity; no explicit guidance supporting this claim.
As a result, atorvastatin absorption and clearance stay the same with a normal amount of alcohol.
No labeling statement asserting unchanged absorption/clearance with moderate alcohol.
Excessive alcohol can saturate or inhibit CYP3A4 and other liver enzymes.
Label does not explicitly describe alcohol saturating/inhibiting CYP3A4 or other liver enzymes in the provided sections.
Saturation or inhibition of these enzymes can potentially raise atorvastatin levels.
Label discusses drug interactions with CYP3A4 inhibitors but does not attribute alcohol-induced enzyme saturation/inhibition to increased atorvastatin levels.
Moderate alcohol consumption has no credible evidence of reducing atorvastatin’s cholesterol-lowering effect.
Not described in labeling.
There is no clear evidence that heavy alcohol reduces atorvastatin’s LDL-lowering potency.
Not described in labeling.
Red wine contains resveratrol.
Not addressed in atorvastatin labeling.
Resveratrol can modestly raise HDL and lower LDL.
Not addressed in labeling.
Polyphenols do not counteract atorvastatin.
Not addressed in labeling.
Up to ~1–2 standard drinks on occasion is unlikely to interfere with Lipitor's effectiveness.
Not addressed in labeling.
Up to ~1–2 standard drinks on occasion is unlikely to interfere with Lipitor's safety profile.
Not addressed in labeling.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Explicit hepatic safety monitoring guidance (e.g., liver function tests before initiation and during therapy) and explicit contraindications for active liver disease, as described in the label, are not captured in the claims.
Importance:
High
Clear statements on the established drug interaction framework with other agents (Table 3 interactions) and graded recommendations when combining with interacting drugs are not fully represented in the claims.
Importance:
High
Monitoring recommendations such as periodic CPK determinations in risk situations, and guidance on when to withhold or discontinue therapy for myopathy, are only partially touched.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most alcohol-related claims are not explicitly supported by the label; label emphasizes hepatic and myopathy risks with statins generally, not alcohol-specific interaction risk. Some accurate points align with label concepts, but many alcohol-specific assertions are not supported.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Overextension of alcohol interaction claims not supported by label; several assertions extrapolate beyond labeling.
Suggested Improvement
Limit claims to those explicitly supported by Sections 5.1, 5.2, 7, 12.3, and 17 of the label; omit or reword statements about alcohol effects on efficacy or absorption unless supported by labeling. Include explicit monitoring and contraindication references from the label.